|Acceleron Speaker:||John Knopf, Ph.D., Chief Executive Officer of Acceleron|
|Date:||March 28, 2014|
|Time:||11:30 AM (EDT)|
|Location:||Room 402/403, Millennium Broadway Hotel & Conference Center|
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.
Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "dead cat bounce" (down big yesterday but up big today) candidate
The Brexit-related market pullback has created stock-buying opportunities. Here are 14 more stocks for investors to consider from Morgan Stanley.